sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: ALL (Acute Lymphatic Leukemia)

Trial: HOVON 117 ALL

1. Overview
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms

return to top


HO117 news

27 January 2016 -Recruitment to the trial is suspended

1. Overview


A phase 2 study for older adults with Acute Lymphoblastic Leukaemia


on hold


University College London in association with HOVON

Validity no: NCT01616238

Type of study

Prospective Phase II study

Type of monitoring for this study

Site evaluation visits

Target number of patients


Current number of patients


Approved by


Study objectives

• Complete remission rate after 2 phases of induction
• EFS at 1 year
• Treatment related mortality
• Complete remission rate after 1 phase of induction
• Prognostic significance of molecularly determined minimal residual disease (MRD) at various time-points during therapy with respect to relapse occurrence.
• Overall Survival at 1 year
• Tolerability of treatment as determined by occurrence of key adverse effects
• Duration of in-patient hospitalisation
• Relationship between performance status/co-morbidity and treatment option chosen
• Quality of life aspects assessed at diagnosis/baseline at various time points.

2. Patient eligibility criteria

Inclusion criteria

• Age ≥ 60 with Acute Lymphoblastic Leukaemia (ALL) OR ≥ 55 with Acute Lymphoblastic Leukaemia (ALL) unsuitable for the UKALL14 or HOVON 100 trial
• Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days may be given before study registration)
• Written informed consent

Exclusion criteria

• Known HIV infection
• Blast transformation of CML
• Mature B-cell leukaemia i.e. Burkitts disease t(8,14)(q24;q32) and variant c-myc translocations e.g. t(2;8)(p12;q24), t(8;22)(q24;q11)
• Women who are pregnant or lactating

3. Registration (& randomization) of patients


At UCL CTC +44 20 7679 9861

Registration criteria

The following information will be requested:

Following pre-treatment evaluations (as detailed in section 5.1), confirmation of eligibility and consent of a patient at a site, the registration form must be fully completed and then faxed to UCL CTC. The faxed registration form will be used to confirm patient eligibility at UCL CTC.
A study number and confirmation of treatment allocation will be assigned for the patient and details added to the form.

4. Participating parties

Principal Investigator(s)

Mw.Dr. A.W. Rijneveld (Erasmus MC - Centrum)

Principal investigator

dr. A. Fielding (UCL)
mw.Dr. A.W. Rijneveld (HOVON)

Trial manager

E. Marwood - UKALL60+ Trial Coordinator (UCL)
I. Meulendijks (HDC)

Central data management


5. Participating sites

Included patients *
NL-Rotterdam-Erasmus MC - Centrum

* Please note that if TOP is not used to register patients for a study, the number of patients shown is zero.

6. Instruction videos

7. Download documentation / forms

return to top